These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38798813)

  • 1. Ketamine in Substance Use Disorder Treatment: A Narrative Review.
    Famuła A; Radoszewski J; Czerwiec T; Sobiś J; Więckiewicz G
    Alpha Psychiatry; 2024 Mar; 25(2):206-211. PubMed ID: 38798813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.
    Martinotti G; Chiappini S; Pettorruso M; Mosca A; Miuli A; Di Carlo F; D'Andrea G; Collevecchio R; Di Muzio I; Sensi SL; Di Giannantonio M
    Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine for the treatment of addiction: Evidence and potential mechanisms.
    Ivan Ezquerra-Romano I; Lawn W; Krupitsky E; Morgan CJA
    Neuropharmacology; 2018 Nov; 142():72-82. PubMed ID: 29339294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unified model of ketamine's dissociative and psychedelic properties.
    Marguilho M; Figueiredo I; Castro-Rodrigues P
    J Psychopharmacol; 2023 Jan; 37(1):14-32. PubMed ID: 36527355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder.
    Strong CE; Kabbaj M
    Front Behav Neurosci; 2020; 14():593860. PubMed ID: 33362485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of ketamine action as an antidepressant.
    Zanos P; Gould TD
    Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.
    Kohtala S
    Pharmacol Rep; 2021 Apr; 73(2):323-345. PubMed ID: 33609274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or Cocaine.
    Gerb SA; Cook JE; Gochenauer AE; Young CS; Fulton LK; Grady AW; Freeman KB
    Comp Med; 2019 Feb; 69(1):29-34. PubMed ID: 30696519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multiscale View of the Mechanisms Underlying Ketamine's Antidepressant Effects: An Update on Neuronal Calcium Signaling.
    Kawatake-Kuno A; Murai T; Uchida S
    Front Behav Neurosci; 2021; 15():749180. PubMed ID: 34658809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review.
    Sepulveda Ramos C; Thornburg M; Long K; Sharma K; Roth J; Lacatusu D; Whitaker R; Pacciulli D; Moredo Loo S; Manzoor M; Tsang YY; Molenaar S; Sundar K; Jacobs RJ
    Cureus; 2022 Mar; 14(3):e23647. PubMed ID: 35505747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine: The final frontier or another depressing end?
    Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
    Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicide prevention and ketamine: insights from computational modeling.
    Charlton CE; Karvelis P; McIntyre RS; Diaconescu AO
    Front Psychiatry; 2023; 14():1214018. PubMed ID: 37457775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine's Antisuicidal Actions.
    Lengvenyte A; Olié E; Courtet P
    Curr Psychiatry Rep; 2019 Dec; 21(12):132. PubMed ID: 31797066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment.
    Ware OD
    Exp Clin Psychopharmacol; 2024 Jun; 32(3):263-269. PubMed ID: 37917509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
    du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine treatment for depression: a review.
    Yavi M; Lee H; Henter ID; Park LT; Zarate CA
    Discov Ment Health; 2022; 2(1):9. PubMed ID: 35509843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
    Averill LA; Fouda S; Murrough JW; Abdallah CG
    Adv Pharmacol; 2020; 89():163-194. PubMed ID: 32616206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action.
    Aleksandrova LR; Wang YT; Phillips AG
    Chronic Stress (Thousand Oaks); 2017; 1():. PubMed ID: 30556028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.